septic-shock

Documents about septic-shock

• Quality Improvement in Infection COntrol and Sepsis Management in MOdel Regions#891555ClinicalTrials.gov
• O-GlcNAc stimulation: A new metabolic approach to treat septic shock#254044HAL (France)
• A 1-Hour Resuscitation Bundle for Prehospital Management of Septic Shock#796299HAL (France)
• Micro and Macro Circulation in Sepsis#813458ClinicalTrials.gov
• Shenfu Injection Improves Arterial Vascular Reactivity#845172ClinicalTrials.gov
• AZD9773 Dose Escalation Study#845227ClinicalTrials.gov
• Cerebral Hemodynamics and Oxygenation in Critically Ill Patients#875750ClinicalTrials.gov
• Pharmacokinetics of Caspofungin#880659ClinicalTrials.gov
• Sepsis Assessment in Belgian Emergency Rooms#896669ClinicalTrials.gov
• Leukocyte MOrphology and CORticosteroids Response in SEPtic Patients (MOCORSEP)#853172ClinicalTrials.gov
• Use of Epoetin Alfa and Iron Derisomaltose in Treatment of Anemia in Patients With Sepsis or Septic Shock: a Randomized Controlled Trial#896617ClinicalTrials.gov
• Effects of Sedatives on Sublingual Microcirculation of Patients With Septic Shock#845725ClinicalTrials.gov
• Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis#346865ClinicalTrials.gov
• Effect of Immunophenotype on Prognosis of Sepsis#806949ClinicalTrials.gov
• Biomarkers in Infection#847538ClinicalTrials.gov
• Monitoring of Septic Shock-induced Immunosuppression#849413ClinicalTrials.gov
• The Role of Dysfunctional HDL in Severe Sepsis#884142ClinicalTrials.gov
• Hypoxia Inducible Factor 1 Alpha as a Novel Biomarker in Septic Shock#902450ClinicalTrials.gov
• Venous to Arterial Carbon Dioxide Difference (P₍ᵥ-ₐ₎CO₂): Predictor of Septic Patient Prognosis Depending on the ScvO₂#865619ClinicalTrials.gov
• Comparison of Angiotensin II to Standard Dose Vasopressors on Change in Arterial Elastance#830525ClinicalTrials.gov
• Image 2_Admission antithrombin III activity as a risk-enrichment marker for septic shock below the ISTH overt-DIC threshold.tif#414776Figshare
• Image 1_Admission antithrombin III activity as a risk-enrichment marker for septic shock below the ISTH overt-DIC threshold.tif#414777Figshare
• Image 4_Admission antithrombin III activity as a risk-enrichment marker for septic shock below the ISTH overt-DIC threshold.tif#414778Figshare
• Image 3_Admission antithrombin III activity as a risk-enrichment marker for septic shock below the ISTH overt-DIC threshold.tif#414779Figshare
• Image 5_Admission antithrombin III activity as a risk-enrichment marker for septic shock below the ISTH overt-DIC threshold.tif#414780Figshare
• Unsupervised Machine Learning for Clustering of Septic Patients to Determine Optimal Treatment#856513ClinicalTrials.gov
• Safety and Feasibility of Metformin for Sepsis Induced AKI#148729ClinicalTrials.gov
• Medical Education for Sepsis Source Control and Antibiotics#148810ClinicalTrials.gov
• Antibiotic De-escalation in Onco-hematology Patients for Sepsis or Septic Shock#300274ClinicalTrials.gov
• Randomized Control Study in REsuscitation of SEpsis Trial#424216ClinicalTrials.gov
• Explainable machine learning for predicting venous thromboembolism in septic shock patients.#427833NCBI PubMed Central
• Endotoxins and Cytokines Removal During Continuous Hemofiltration With oXiris™#807241ClinicalTrials.gov
• Release of Nociceptin From Granulocytes in Sepsis#841842ClinicalTrials.gov
• IL 6 Measurement Using a New Densitometric Bedside (POC) Test#848365ClinicalTrials.gov
• Prospective Study Evaluating the Prevalence of Intestinal Dysfunction#869808ClinicalTrials.gov
• Therapeutic Plasma Exchange Adsorption Diafiltration#881121ClinicalTrials.gov
• POC SPLA2-IIA as a Biomarker for Sepsis and Septic Shock#889859ClinicalTrials.gov
• Supplementary file 1_Admission antithrombin III activity as a risk-enrichment marker for septic shock below the ISTH overt-DIC threshold.docx#414775Figshare
• The effects of ultra-selective beta1-antagonism on the metabolic and cytokine profile in septic shock patients receiving noradrenaline: a sub-investigation from the STRESS-L Randomised Study#457919Spiral
• Sepsis Early EvaluatioN Through Rapid Ultrasound and veNous Gas Analysis#1007798ClinicalTrials.gov
• Paramedic Initiated Treatment of Sepsis Targeting Out-of-hospital Patients (PITSTOP)#154676ClinicalTrials.gov
• Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2026#254188HAL (France)
• Study into the Reversal of Septic Shock with Beta Blockade (Landiolol): the STRESS-L randomised trial#415220NCBI Bookshelf
• Next-Generation Sequencing Diagnostics of Bacteremia in Sepsis#807063ClinicalTrials.gov
• Musculoskeletal Ultrasound Study in Critical Care: Longitudinal Evaluation#835221ClinicalTrials.gov
• Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients#890148ClinicalTrials.gov
• Short-course Antimicrobial Therapy in Sepsis#899476ClinicalTrials.gov
• Effects of Anisodamine on Sublingual Microcirculation and Vascular Waterfall Phenomenon in Patients With Septic Shock#900488ClinicalTrials.gov
• Validation of a Capillary Leak Index During Septic Shock, Based on Haemoglobin Level Variations Induced by Fluid Resuscitation. A Pilot Study.#1033142ClinicalTrials.gov
• Early Methylene Blue in the Microhemodynamics of Septic Patients#849858ClinicalTrials.gov